Key terms
About CYT
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CYT news
No recent news articles are available for CYT
No recent press releases are available for CYT
CYT Financials
Key terms
Ad Feedback
CYT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CYT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range